AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19169898 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin with fluid therapy
Number of subjects: 200
Study 17824470 — intervention group
Group type: EXPERIMENTAL
Intervention: Isapgol (5.6 g twice daily) + Atorvastatin (10 mg once daily)
Number of subjects: 100
Study 17824470 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg once daily)
Number of subjects: 100
Study 17824470 — intervention group
Group type: EXPERIMENTAL
Intervention: Isapgol + Atorvastatin
Number of subjects: 100
Study 17824470 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 100
Study 15753147 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (200 IU/day)
Number of subjects: 617
Study 11477966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (three doses at weekly intervals)
Number of subjects: 1803
Study 11477966 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracycline (daily over 6 weeks)
Number of subjects: 1803
Study 9930041 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on heart failure and self management with follow up at a nurse directed outpatient clinic for one year after discharge
Number of subjects: 190
Study 9930041 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice management
Number of subjects: 190
Study 1479050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 5 mg/day
Number of subjects: 1109
Study 1479050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 1109
Study 1479050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 1109
Study 1479050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 1109
Study 1479050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1109
Study 3969862 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-verapamil
Number of subjects: 16
Study 3969862 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-nifedipine
Number of subjects: 16
Study 3969862 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 16
Study 31522985 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg
Number of subjects: 64
Study 31522985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30085122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 30085122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27609148 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-scale nursing homes
Number of subjects: 314
Study 27609148 — intervention group
Group type: COMPARATOR
Intervention: Large-scale nursing homes
Number of subjects: 314
Study 24150249 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + Sertraline
Number of subjects: 73
Study 24150249 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Placebo
Number of subjects: 73
Study 24150249 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + Placebo
Number of subjects: 73
Study 24150249 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + Sertraline
Number of subjects: 73
Study 23211895 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol pulpotomy (FC)
Number of subjects: 74
Study 23211895 — intervention group
Group type: COMPARATOR
Intervention: Vitapex(®) pulpectomy (RCT)
Number of subjects: 74
Study 19574869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group U)
Number of subjects: 70
Study 19574869 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (group S)
Number of subjects: 70
Study 17402665 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a small set of other-race 'friends' for 1 hour
Number of subjects: 0
Study 17402665 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of faces in the periphery (perceptual stress)
Number of subjects: 0
Study 17402665 — intervention group
Group type: EXPERIMENTAL
Intervention: Test for faces and nonface objects (dogs)
Number of subjects: 0
Study 15189091 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 31
Study 15189091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 31
Study 15189091 — intervention group
Group type: EXPERIMENTAL
Intervention: Areolar regions in premenopausal women
Number of subjects: 31
Study 15189091 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy breast tissue
Number of subjects: 31
Study 15189091 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric positions within individuals
Number of subjects: 31
Study 11441903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 40 microg/kg/h
Number of subjects: 40
Study 11441903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 300 microg/kg/h
Number of subjects: 40
Study 11441903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 600 microg/kg/h
Number of subjects: 40
Study 11441903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 11441903 — intervention group
Group type: EXPERIMENTAL
Intervention: All hydrocortisone groups
Number of subjects: 40
Study 9881885 — intervention group
Group type: EXPERIMENTAL
Intervention: L. casei Shirota-fermented milk (100 ml three times daily for 4 weeks)
Number of subjects: 20
Study 9881885 — intervention group
Group type: COMPARATOR
Intervention: Control group (unfermented milk, 100 ml three times daily for 4 weeks)
Number of subjects: 20
Study 9881885 — intervention group
Group type: EXPERIMENTAL
Intervention: L. casei Shirota-fermented milk
Number of subjects: 20
Study 7626438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Short Stay Spinal Surgical Unit
Number of subjects: 85
Study 2507181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (200 micrograms.kg‐1 bolus + 50 micrograms.kg‐1.hr‐1 infusion)
Number of subjects: 0
Study 2507181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2507181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (other dosages: 100 micrograms.kg‐1 + 25 micrograms.kg‐1.hr‐1 and 50 micrograms.kg‐1 + 12.5 micrograms.kg‐1.hr‐1)
Number of subjects: 0
Study 309931 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 43
Study 309931 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 43
Study 31771038 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic microfracture technique in combination with autologous bone marrow stem cells transplantation
Number of subjects: 46
Study 30953483 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention via WeChat
Number of subjects: 222
Study 30953483 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 222
Study 28715712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1mA
Number of subjects: 33
Study 28715712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2mA
Number of subjects: 33
Study 28715712 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 33
Study 26010884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment strategy using FOLFIRI.3 and gemcitabine (Arm 2)
Number of subjects: 98
Study 26010884 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (Arm 1)
Number of subjects: 98
Study 23670358 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD drinks (4°C)
Number of subjects: 8
Study 23670358 — intervention group
Group type: COMPARATOR
Intervention: WARM drinks (28°C)
Number of subjects: 8
Study 21633948 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 120
Study 21633948 — intervention group
Group type: COMPARATOR
Intervention: Cryostripping
Number of subjects: 120
Study 19303015 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0
Study 19303015 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 0
Study 19303015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (IKK inhibitor)
Number of subjects: 0
Study 19303015 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (AT1 antagonist)
Number of subjects: 0
Study 19303015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17409897 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with advanced NSCLC
Number of subjects: 1157
Study 17409897 — intervention group
Group type: COMPARATOR
Intervention: Men with advanced NSCLC
Number of subjects: 1157
Study 15243278 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate (ALN) 70 mg
Number of subjects: 456
Study 15243278 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (RLX) 60 mg daily
Number of subjects: 456
Study 11061584 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 2 weeks
Number of subjects: 20
Study 9029461 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain/Vitapan teeth
Number of subjects: 70
Study 9029461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivoclar Orthosit
Number of subjects: 70
Study 9029461 — intervention group
Group type: COMPARATOR
Intervention: Other denture teeth (Premierdent, Acrotone, Rx1, Duravite)
Number of subjects: 70
Study 8287341 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with a bismuth compound, metronidazole and either amoxicillin or tetracycline
Number of subjects: 14
Study 8287341 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori therapy added to conventional ulcer treatment
Number of subjects: 14
Study 8287341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 4 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 8 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.375 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.75 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1.5 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 3 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 6 mg
Number of subjects: 5
Study 2457074 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 30869991 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 118
Study 30869991 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 118
Study 30869991 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 118
Study 30869991 — intervention group
Group type: COMPARATOR
Intervention: Acupressure and Sham Acupressure
Number of subjects: 118
Study 31228287 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric method when Shapiro-Wilk P > 0.2
Number of subjects: 120
Study 31228287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric method
Number of subjects: 120
Study 31228287 — intervention group
Group type: EXPERIMENTAL
Intervention: Box-Cox transformation parametric method
Number of subjects: 120
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 12 weeks
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (treatment-experienced)
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (treatment-experienced, relapsed after interferon therapy)
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (HCV GT2a infection)
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (HCV GT2b infection)
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 12 weeks (HCV GT2a infection)
Number of subjects: 171
Study 28536999 — intervention group
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 12 weeks (HCV GT2b infection)
Number of subjects: 171
Study 25680390 — intervention group
Group type: EXPERIMENTAL
Intervention: STeleR intervention
Number of subjects: 52
Study 25680390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 22605788 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking feedback
Number of subjects: 3980
Study 22605788 — intervention group
Group type: COMPARATOR
Intervention: Non-benchmarked feedback
Number of subjects: 3980
Study 21724265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50mg/day p.o.)
Number of subjects: 38
Study 21724265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19758440 — intervention group
Group type: EXPERIMENTAL
Intervention: HR+/HER2+ tumors
Number of subjects: 116
Study 19758440 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-/HER2- tumors
Number of subjects: 116
Study 19758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 labeling index
Number of subjects: 116
Study 19758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Biology-based tumor type
Number of subjects: 116
Study 19758440 — intervention group
Group type: EXPERIMENTAL
Intervention: HR+/HER2- tumors
Number of subjects: 116
Study 19758440 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-/HER2+ tumors
Number of subjects: 116
Study 16769215 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral joint replacement (PFJR)
Number of subjects: 103
Study 16769215 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrevised knees without preoperative trochlear dysplasia
Number of subjects: 103
Study 16769215 — intervention group
Group type: COMPARATOR
Intervention: Unrevised knees with preoperative trochlear dysplasia
Number of subjects: 103
Study 15259324 — intervention group
Group type: EXPERIMENTAL
Intervention: First target (T1) presented at fixation, second target (T2) varied in location and timing.
Number of subjects: 1
Study 11128665 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg daily)
Number of subjects: 191
Study 11128665 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75-150 mg daily)
Number of subjects: 191
Study 11128665 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 191
Study 11128665 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 191
Study 9048712 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT SPECT in patients with early Parkinson's disease
Number of subjects: 18
Study 9048712 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT SPECT in patients with advanced Parkinson's disease
Number of subjects: 18
Study 9048712 — intervention group
Group type: COMPARATOR
Intervention: Control group (age matched healthy volunteers)
Number of subjects: 18
Study 9048712 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT SPECT in Parkinson's disease patients
Number of subjects: 18
Study 8038023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 24
Study 8038023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 2869745 — intervention group
Group type: EXPERIMENTAL
Intervention: N-propylnorapomorphine (19 mg oral dose)
Number of subjects: 0
Study 2869745 — intervention group
Group type: EXPERIMENTAL
Intervention: N-propylnorapomorphine (subchronic dosage schedule)
Number of subjects: 0
Study 31805549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Dorzolamide for one week
Number of subjects: 0
Study 31805549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic gas mixture breathing
Number of subjects: 0
Study 29858000 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 28.8 μg
Number of subjects: 248
Study 29858000 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 14.4 μg
Number of subjects: 248
Study 29858000 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 7.2 μg
Number of subjects: 248
Study 29858000 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 3.6 μg
Number of subjects: 248
Study 29858000 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 1.9 μg
Number of subjects: 248
Study 29858000 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 248
Study 29858000 — intervention group
Group type: EXPERIMENTAL
Intervention: SAL DPI 50 μg
Number of subjects: 248
Study 27608921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch ad libitum
Number of subjects: 154
Study 27608921 — intervention group
Group type: COMPARATOR
Intervention: No lunch
Number of subjects: 154
Study 24530156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact ovaries
Number of subjects: 222
Study 24530156 — intervention group
Group type: COMPARATOR
Intervention: Prior oophorectomy
Number of subjects: 222
Study 23539002 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Unna boot
Number of subjects: 32
Study 23539002 — intervention group
Group type: COMPARATOR
Intervention: Simple bandage application
Number of subjects: 32
Study 21234625 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted school-based drama group therapy (DGT)
Number of subjects: 0
Study 21234625 — intervention group
Group type: COMPARATOR
Intervention: Teaching maths and English
Number of subjects: 0
Study 18497346 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone
Number of subjects: 180
Study 18497346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 17066611 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and mucosal plication (RAMP)
Number of subjects: 46
Study 17066611 — intervention group
Group type: COMPARATOR
Intervention: Ligature and excision procedure (LEP)
Number of subjects: 46
Study 12594112 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 70
Study 12594112 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment (group 1)
Number of subjects: 70
Study 12594112 — intervention group
Group type: COMPARATOR
Intervention: Simulated treatment (group 2)
Number of subjects: 70
Study 11020616 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Corneal Shaper (ACS) microkeratome
Number of subjects: 137
Study 11020616 — intervention group
Group type: COMPARATOR
Intervention: Hansatome microkeratome
Number of subjects: 137
Study 9028062 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pneumothorax
Number of subjects: 57
Study 9028062 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with antituberculous drugs and corticosteroids
Number of subjects: 57
Study 2064144 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MTH) challenge
Number of subjects: 16
Study 6293264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic treatment with chlorambucil, methotrexate and 5‐fluorouracil
Number of subjects: 0
Study 6293264 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and 5‐fluorouracil
Number of subjects: 0
Study 31608552 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 0
Study 31608552 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 0
Study 31608552 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 31574794 — intervention group
Group type: EXPERIMENTAL
Intervention: Heyan Kuntai Capsule (HYKT)
Number of subjects: 100
Study 31574794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27345931 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled levodopa formulation (CVT-301)
Number of subjects: 86
Study 27345931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24995515 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon (various doses/regimens)
Number of subjects: 141
Study 24995515 — intervention group
Group type: COMPARATOR
Intervention: Pegylated‐interferon‐α2a
Number of subjects: 141
Study 23523026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted extraction of phenolic compounds using 1g plant sample with 12 mL of 35% ethanol for 40 min.
Number of subjects: 0
Study 23523026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted extraction of phenolic compounds
Number of subjects: 0
Study 23523026 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected extract from ultrasound-assisted extraction
Number of subjects: 0
Study 21078951 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐488043 800 mg
Number of subjects: 30
Study 21078951 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐488043 1,800 mg
Number of subjects: 30
Study 21078951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21078951 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐488043
Number of subjects: 30
Study 19588284 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine spray (S)
Number of subjects: 1864
Study 19588284 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous lidocaine (V)
Number of subjects: 1864
Study 16723058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 0.1 mg kg‐1 (Group N)
Number of subjects: 47
Study 16723058 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group P)
Number of subjects: 47
Study 15078044 — intervention group
Group type: EXPERIMENTAL
Intervention: Active navigation
Number of subjects: 0
Study 15078044 — intervention group
Group type: COMPARATOR
Intervention: Passive learning
Number of subjects: 0
Study 15078044 — intervention group
Group type: EXPERIMENTAL
Intervention: Map learning
Number of subjects: 0
Study 15078044 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigating in a real environment
Number of subjects: 0